A Peptide Nasal Spray That Reboots Reproductive Hormones — First Human Trial Results

Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Kisspeptin is an investigational therapy and is not approved for reproductive disorder treatment. Consult a licensed reproductive endocrinologist before considering any hormone-related treatment.

Kisspeptin is a peptide that occupies a critical position in the reproductive hormone cascade: it is the primary signal that activates gonadotropin-releasing hormone (GnRH) neurons in the hypothalamus, which in turn drive the pituitary to release luteinizing hormone (LH) and follicle-stimulating hormone (FSH), which then signal the gonads to produce sex hormones and regulate fertility.

Until recently, administering kisspeptin required intravenous or subcutaneous injection — limiting its clinical practicality to research settings. A study published in EBioMedicine in May 2025 changes that picture substantially. Researchers from Imperial College London and collaborators in France demonstrated that intranasal kisspeptin-54 can robustly and safely stimulate gonadotropin release in humans — including in women with hypothalamic amenorrhoea, a condition where the reproductive hormone axis shuts down.

The Background: When the Reproductive Axis Goes Quiet

The hypothalamic-pituitary-gonadal (HPG) axis is the control system for reproductive hormones. It is regulated by a pulsatile signal: GnRH neurons in the hypothalamus fire in a rhythm, triggering LH and FSH pulses from the pituitary, which govern ovulation in women and sperm production in men.

Kisspeptin neurons are the upstream drivers of that rhythm. When kisspeptin signaling falters — due to low body weight, extreme exercise, chronic stress, or other metabolic signals — GnRH firing slows or stops, and the reproductive axis goes quiet. This is the mechanism underlying:

Hypothalamic amenorrhoea (HA) — loss of menstrual periods in women, often associated with athletic training, low BMI, or caloric restriction
Functional hypogonadism — in men, chronic stress, significant weight loss, or medical illness can suppress the same axis
Various forms of reproductive dysfunction where the primary problem is hypothalamic, not ovarian or testicular

These patients have working gonads. Their ovaries or testes can produce hormones if properly stimulated. The problem is the upstream signal.

The Trial: What They Tested

The study used a randomized, double-blinded, crossover, placebo-controlled design — the gold standard for evaluating a pharmacological intervention. Participants included healthy men, healthy women, and women with hypothalamic amenorrhoea. They received intranasal kisspeptin-54 or placebo on separate occasions, with reproductive hormone levels measured over several hours.

The delivery mechanism was a standard nasal spray. Researchers also tested the stability of the kisspeptin formulation and conducted mechanistic studies in rodents to understand how nasal delivery might work differently from injection.

The Results

The trial produced clear and consistent findings:

Intranasal kisspeptin-54 significantly increased LH levels in all participant groups — healthy men, healthy women, and women with hypothalamic amenorrhoea
Effects were rapid, appearing within the monitoring window post-administration
No adverse events were observed with the intranasal route
The formulation was stable for 60 days at 4°C, addressing a major practical concern for clinical use

In women with hypothalamic amenorrhoea specifically — the patient population most likely to benefit therapeutically — the LH response was meaningful. This is significant because HA is a reversible condition if its underlying cause can be addressed, but existing treatments are limited and mostly require injectable routes.

The Mechanism: Why the Nose?

The mechanistic studies revealed something anatomically interesting: kisspeptin accumulates in the olfactory epithelium (the sensory lining of the nasal cavity), and kisspeptin receptors are expressed on GnRH neurons in the olfactory bulb. These olfactory GnRH neurons appear to communicate with the main hypothalamic GnRH population.

This may explain why intranasal delivery can work — the kisspeptin peptide doesn’t need to travel through systemic circulation to reach the hypothalamus; it may interact with this local olfactory-hypothalamic relay instead. It’s an anatomically elegant pathway, and it aligns with why reproductive function in many species is linked to olfactory cues.

Why This Matters

Hypothalamic amenorrhoea affects a substantial and often underdiagnosed population: female athletes, women who have lost significant weight, and those with eating disorder histories. Current management relies primarily on behavioral intervention (weight restoration, reduced exercise intensity) and sometimes injectable gonadotropin therapy for fertility — with all the logistical and physiological complexity that entails.

A stable, non-invasive nasal spray that can reactivate the reproductive hormone axis would be a meaningful advance in this space. The trial establishes that kisspeptin-54 via nasal route can do exactly what it needs to do pharmacologically: stimulate the upstream hormone signal.

What Is Not Yet Known

This is a proof-of-concept and mechanism trial, not a full clinical efficacy study. Important questions remain:

Does a single LH pulse translate to restored cycles? Stimulating one hormone pulse is different from restoring the rhythmic pulsatility needed for normal cycling and ovulation.
What dose and frequency would be needed clinically? The optimal regimen for sustained effect hasn’t been established.
Long-term safety and efficacy data are not yet available.
Regulatory approval is distant. Kisspeptin is investigational. No product is approved for reproductive disorder treatment.

What This Means for Patients

If you have been diagnosed with hypothalamic amenorrhoea or are experiencing reproductive hormone suppression, this research is relevant context:

The mechanism is real. Kisspeptin is a genuine regulator of the HPG axis — this is not fringe science.
Clinical applications are coming, but not here yet. This is a Phase I/mechanism study. Therapeutic availability is years away, pending further trials.
Behavioral causes matter. HA secondary to low weight or exercise excess often responds to behavioral correction. That remains the primary intervention.
Be wary of unregulated sources. Kisspeptin is not an approved drug. Purchasing it from online peptide vendors bypasses all the safety verification this clinical trial represents.
Consult a reproductive endocrinologist if you have concerns about hypothalamic function.

Source

Mills EG, Silva MSB, Delli V, et al. “Intranasal kisspeptin administration rapidly stimulates gonadotropin release in humans.” EBioMedicine. May 2025 (epub April 11, 2025). PMID: 40215751